Compare FIVN & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | HROW |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | 373 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2014 | N/A |
| Metric | FIVN | HROW |
|---|---|---|
| Price | $25.40 | $42.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | $26.06 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 2.5M | 796.4K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,149,088,000.00 | N/A |
| Revenue This Year | $11.39 | $31.62 |
| Revenue Next Year | $10.00 | $50.77 |
| P/E Ratio | $118.71 | ★ N/A |
| Revenue Growth | ★ 10.28 | N/A |
| 52 Week Low | $13.29 | $28.54 |
| 52 Week High | $29.64 | $54.98 |
| Indicator | FIVN | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 67.76 | 54.82 |
| Support Level | $17.38 | $40.56 |
| Resistance Level | $26.93 | $44.50 |
| Average True Range (ATR) | 1.21 | 2.11 |
| MACD | 0.50 | -0.07 |
| Stochastic Oscillator | 95.32 | 27.70 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.